Whitening and Anti-oxidative Activities of Chemical Components Extracted from Branches of Sorbus alnifolia
TableS1.
1H and 13C NMR data of compound 1 (400 and 100 MHz, pyridine-d5)
|
No.
|
Compound 1 |
|
δ H (int, multi, JHz)
|
δ C |
|
1
|
2.50 (2H, d, 12.4)
|
54.3
|
|
2
|
|
211.8
|
|
3
|
4.23 (1H, s)
|
84.0
|
|
4
|
|
46.4
|
|
5
|
|
55.4
|
|
6
|
|
19.7
|
|
7
|
|
33.7
|
|
8
|
|
41.2
|
|
9
|
|
47.9
|
|
10
|
|
44.2
|
|
11
|
|
25.1
|
|
12
|
5.59 (1H, t, 3.2)
|
127.9
|
|
13
|
|
140.6
|
|
14
|
|
42.8
|
|
15
|
|
29.9
|
|
16
|
|
26.9
|
|
17
|
|
48.8
|
|
18
|
3.17 (1H, s)
|
55.1
|
|
19
|
|
73.2
|
|
20
|
|
42.9
|
|
21
|
|
27.6
|
|
22
|
|
39.0
|
|
23
|
1.34 (3H, s)
|
30.0
|
|
24
|
0.90 (3H, s)
|
17.4
|
|
25
|
1.06 (3H, s)
|
16.9
|
|
26
|
0.90 (3H, s)
|
17.9
|
|
27
|
1.76 (3H, s)
|
24.4
|
|
28
|
|
181.3
|
|
29
|
1.47 (3H, s)
|
27.5
|
|
30
|
1.15 (3H, d, 5.9)
|
17.3
|
FigureS1.
1H and 13C NMR spectra of compound 1 in pyridine-d5.
Compound 1
HR-ESI-MS: m/z 485.32630 [M-H]- (calcd for C30H45O5, m/z 485.32725).
FigureS2.
HR-ESI-MS spectrum of compound 1.
TableS2.
1H and 13C NMR data of compound 2 (400 and 100 MHz, pyridine-d5)
|
No.
|
Compound 2 |
|
δ H (int, multi, JHz)
|
δ C |
|
1
|
|
42.8
|
|
2
|
4.32 (1H, m)
|
66.6
|
|
3
|
3.78 (1H, d, 2.8)
|
79.8
|
|
4
|
|
39.3
|
|
5
|
|
49.2
|
|
6
|
|
19.1
|
|
7
|
|
34.0
|
|
8
|
|
41.0
|
|
9
|
|
48.1
|
|
10
|
|
39.1
|
|
11
|
|
24.5
|
|
12
|
5.60 (1H, t-like)
|
128.4
|
|
13
|
|
140.4
|
|
14
|
|
43.3
|
|
15
|
|
29.9
|
|
16
|
|
26.8
|
|
17
|
|
48.7
|
|
18
|
3.06 (1H, s)
|
55.0
|
|
19
|
|
73.1
|
|
20
|
|
42.6
|
|
21
|
|
27.4
|
|
22
|
|
39.0
|
|
23
|
1.28 (3H, s)
|
30.5
|
|
24
|
0.92 (3H, s)
|
22.7
|
|
25
|
1.00 (3H, s)
|
17.1
|
|
26
|
1.13 (3H, s)
|
17.7
|
|
27
|
1.66 (3H, s)
|
25.1
|
|
28
|
|
181.2
|
|
29
|
1.43 (3H, s)
|
27.5
|
|
30
|
1.13 (3H, d, 6.4)
|
17.3
|
FigureS3.
1H and 13C NMR spectra of compound 2 in pyridine-d5.
Compound 2
HRESI-MS: m/z 487.34310 [M-H]- (calcd for C30H47O5, m/z 487.34290).
FigureS4.
HR-ESI-MS spectrum of compound 2.
TableS3.
1H and 13C NMR data of compound 3 (400 and 100 MHz, CD3OD)
|
No.
|
Compound 3 |
|
δ H (int, multi, JHz)
|
δ C |
|
2
|
4.82 (1H, s)
|
80.0
|
|
3
|
4.18 (1H, m)
|
67.6
|
|
4
|
2.86 (1H, dd, 16.5, 4.6)
2.74 (1H, dd, 16.5, 2.8)
|
29.4
|
|
5
|
|
158.1
|
|
6
|
5.94 (1H, d, 2.3)
|
96.5
|
|
7
|
|
157.8
|
|
8
|
5.92 (1H, d, 2.3)
|
96.0
|
|
9
|
|
157.5
|
|
10
|
|
100.2
|
|
1’
|
|
132.4
|
|
2’
|
6.97 (1H, d, 1.8)
|
115.4
|
|
3’
|
|
146.1
|
|
4’
|
|
145.9
|
|
5’
|
6.76 (1H, d, 8.2)
|
116.0
|
|
6’
|
6.80 (1H, dd, 8.2, 1.8)
|
119.5
|
FigureS5.
1H and 13C NMR spectra of compound 3 in CD3OD.
Compound 3
HR-ESI-MS: m/z 289.07258 [M-H]- (calcd for C15H13O6, m/z 289.07176).
FigureS6.
HR-ESI-MS spectrum of compound 3.
TableS4.
1H and 13C NMR data of compound 4 (400 and 100 MHz, CD3OD)
|
No.
|
Compound 4 |
|
δ H (int, multi, JHz)
|
δ C |
|
1
|
|
119.6
|
|
2
|
5.92 (1H, s)
|
68.5
|
|
3
|
|
135.0
|
|
4
|
7.58-7.60 ( 1H, overlapped)
|
130.3
|
|
5
|
7.45-7.47 ( 1H, overlapped)
|
129.1
|
|
6
|
7.45-7.47 ( 1H, overlapped)
|
131.2
|
|
7
|
7.45-7.47 ( 1H, overlapped)
|
129.1
|
|
8
|
7.58-7.60 ( 1H, overlapped)
|
130.3
|
|
1’
|
4.24 (1H, d, 7.3)
|
102.1
|
|
2’
|
3.20-3.35 (1H, overlapped)
|
74.9
|
|
3’
|
3.20-3.35 (1H, overlapped)
|
78.0
|
|
4’
|
3.20-3.35 (1H, overlapped)
|
71.6
|
|
5’
|
3.20-3.35 (1H, overlapped)
|
78.5
|
|
6’
|
3.92 (1H, dd, 11.9, 2.3)
3.70 (1H, dd, 11.9, 6.0)
|
62.9
|
FigureS7.
1H and 13C NMR spectra of compound 4 in CD3OD.
Compound 4
HR-ESI-MS: m/z 340.10404 [M+HCOO]- (calcd for C15H18NO8, m/z 340.10379).
HR-ESI-MS: m/z 294.09747 [M-H]- (calcd for C14H16NO6, m/z 294.09831)).
FigureS8.
HR-ESI-MS spectrum of compound 4.
